The shareholders’ right to decide on the Company’s affairs is exercised at its highest decision-making body – the general meeting (the annual general meeting or an extraordinary general meeting). The general meeting decides, for example, on changes to the articles of association, the election of the Board of Directors and auditors, adoption of the income statement and balance sheet, discharge from liability of the Board of Directors and the CEO, the appropriation of profit or loss, the principles for the appointment of the nomination committee and remuneration guidelines for senior executives.
General meetings shall be held in Lund. Notice convening the annual general meetings and extraordinary general meetings where amendments to the articles of association are to be addressed, shall be issued no earlier than six weeks and no later than four weeks prior to the meeting. Notice convening other extraordinary general meetings shall be issued no earlier than six weeks and no later than three weeks prior to the meeting. Notice shall be published in the Swedish National Gazette (Sw. Post- och Inrikes Tidningar) and by making the notice available on the Company’s website. Information regarding the notice shall at the same time be advertised in Dagens Industri.
Annual General Meeting 2025
The Annual General Meeting is to be held on Wednesday May 7, 2025. Shareholders wishing to submit proposals or comments to the Nomination Committee may do so via email to info@alligatorbioscience.com marked “Att. Nomination committee” or by letter to Alligator Bioscience AB, Nomination Committee, Medicon Village, 223 81 Lund, Sweden. To ensure that the proposals can be considered by the Nomination Committee, proposals shall be submitted in due time before the Annual General Meeting, but not later than 31 January 2025.